Multi-drug resistance protein 2 (MRP2) expression, adjuvant tamoxifen therapy, and risk of breast cancer recurrence: a Danish population-based nested case-control study.
Cathrine Fonnesbech HjorthAnja S NielsenHenrik Toft SorensenTimothy L LashPer DamkierStephen Jacques Hamilton-DutoitDeirdre P Cronin-FentonPublished in: Acta oncologica (Stockholm, Sweden) (2018)
MRP2 expression is neither a predictive marker of tamoxifen effectiveness nor a prognostic marker in breast cancer.